NCT00686686View on ClinicalTrials.gov

Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00686686 - Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED) | Biotech Hunter | Biotech Hunter